A Dietary Supplement Containing Fucoidan Preserves Endothelial Glycocalyx through ERK/MAPK Signaling and Protects against Damage Induced by CKD Serum

Fucoidan Preserves Endothelial Glycocalyx

NuLife Sciences, a BioRegenx, Inc., company, announces the release of a new peer-reviewed study published in the International Journal of Molecular Sciences on the use of Endocalyx Pro™ to protect the glycocalyx on endothelial cells exposed to kidney patients’ plasma.

This study, focused on kidney patients, reveals that the patented formulation of Endocalyx Pro restores the endothelial glycocalyx when exposed to toxic hemodialysis plasma. A healthy endothelial glycocalyx facilitates the exchange of nutrients, hormones, and oxygen, along with removal of waste and carbon dioxide, from all vital organs.

The study is titled “A Dietary Supplement Containing Fucoidan Preserves Endothelial Glycocalyx through ERK/MAPK Signaling and Protects against Damage Induced by CKD Serum,” The authors of the study included researchers from University Hospital Münster, Maastricht University, and Dr. Hans Vink, Chief Science Officer of BioRegenx and Robert M. Long, Chairman of the Board for BioRegenx. Both Dr. Vink and Mr. Long are the co-innovators of Endocalyx Pro™ and GlycoCheck software technology. GlycoCheck,along with other measurement modalities, were used in this study to measure the endothelial glycocalyx and was a critical tool used in this breakthrough study. BioRegenx subsidiary Microvascular Health Solutions is the exclusive worldwide distributor of GlycoCheck, As a subsidiary of BioRegenx, GlycoCheck is available through NuLife Sciences.

Patients with Chronic Kidney Disease (CKD) have a very high risk of cardiovascular disease and premature death when they need to be treated with hemodialysis to detoxify their blood when their kidneys are failing. The toxins in the blood of hemodialysis CKD patients damage their blood vessels, and many recent studies have demonstrated that the increased cardiovascular risk is associated with damage of the endothelial glycocalyx, a protective gel-like polysaccharide matrix on the luminal surface of the vascular endothelium.

“Although many studies confirm that a damaged glycocalyx is related to cardiovascular complications and is associated with poor outcomes for critically ill patients in the ICU, therapeutic options that target to protect, repair, or restore the endothelial glycocalyx are still lacking,” said Dr. Vink. “It is therefore very exciting that the recently published study by Manuel Regier and Carolin Drost and our colleagues investigated the potential of the dietary supplement Endocalyx Pro to protect and restore the endothelial glycocalyx in the presence of toxic hemodialysis plasma.”

Not only was Endocalyx Pro able to restore the dimension of the endothelial glycocalyx after damage by the hemodialysis plasma samples, but the study also demonstrated that Endocalyx Pro could prevent endothelial glycocalyx damage in the presence of the glycocalyx degrading enzyme heparinase, levels of which are high in the blood of hemodialysis patients.

In addition to these exciting, protective, and restorative properties of Endocalyx Pro in an acute model of endothelial glycocalyx damage by exposure to toxic hemodialysis plasma, the authors also demonstrated that adding Endocalyx Pro to the food of mice for only two weeks, resulted in significant uptake of Endocalyx Pro in the blood of these mice, which resulted in a thicker glycocalyx in mice eating the supplement as measured using the GlycoCheck patented software.

Finally, the study demonstrated that several specific cellular pathways, as well as inhibition of the enzyme heparinase, are involved in the protective and restorative effect of Endocalyx in the context of enzymatic and chronic kidney disease-induced damage of the endothelial glycocalyx.

“This groundbreaking study is a huge win for the medical field and patients with CKD,” said William Resides, NuLife Sciences CEO. “We’re proud to be a distributor of Endocalyx Pro and GlycoCheck as part of our mission to provide health solutions for anti-aging and longevity.”

About Endocalyx Pro and GlycoCheck

Endocalyx Pro™ was developed by Mr. Long and Dr. Vink and is patented in U.S., Japan, South Korea, China, and pending in Canada and Europe as a method of supporting the health of the endothelial glycocalyx. Endocalyx Pro™ is the only proprietary, patented anti-aging supplement that has been clinically shown to maintain a healthy endothelial glycocalyx, resulting in the protection of capillary function. Multiple double-blind placebo studies are underway on the effectiveness of Endocalyx Pro on various health conditions. Learn more about these studies at nulifesciences.com.

GlycoCheck was used in this study, and it is an FDA registered Class 1 medical testing device. GlycoCheck measures and analyzes microvascular health, and objectively reports a MicroVascular Health Report. It has been used in more than 100 peer-reviewed research studies worldwide. GlycoCheck is patented in the U.S., Canada, Europe, China, and Japan. BioRegenx subsidiary Microvascular Health Solutions is the exclusive worldwide distributor of GlycoCheck and the upgraded complete GlycoCheck system software, including the new CapiVision™ camera.

About NuLife Sciences

GlycoCheck™ and Endocalyx Pro™ are available through NuLife Sciences, a marketing and distribution company whose mission is to harness advanced technologies to redefine health and longevity from the inside out. NuLife Sciences achieves this by increasing understanding of the biology that controls lifespan and anti-aging in the human body. NuLife Sciences represents best in class products that enable people to lead longer and healthier lives.

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to treat, cure, prevent or diagnose any disease.